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Pancreatic beta-cell function andmass aremarkedly adaptive to compensate for the changes in insulin requirement observed during
several situations such as pregnancy, obesity, glucocorticoids excess, or administration. This requires a beta-cell compensation
which is achieved through a gain of beta-cell mass and function. Elucidating the physiological mechanisms that promote functional
beta-cell mass expansion and that protect cells against death, is a key therapeutic target for diabetes. In this respect, several recent
studies have emphasized the instrumental role ofmicroRNAs in the control of beta-cell function.MicroRNAs are negative regulators
of gene expression, and are pivotal for the control of beta-cell proliferation, function, and survival. On the one hand, changes in
specific microRNA levels have been associated with beta-cell compensation and are triggered by hormones or bioactive peptides
that promote beta-cell survival and function. Conversely, modifications in the expression of other specificmicroRNAs contribute to
beta-cell dysfunction and death elicited by diabetogenic factors including, cytokines, chronic hyperlipidemia, hyperglycemia, and
oxidized LDL. This review underlines the importance of targeting the microRNA network for future innovative therapies aiming
at preventing the beta-cell decline in diabetes.
1. Introduction
Theconcentration of glucose in the blood is tightlymonitored
by the pancreatic islet beta-cell production of insulin. The
main function of insulin is to reduce blood glucose levels by
triggering the uptake and the storage of this carbohydrate by
the cells of the body.The quantity of insulin released by beta-
cells varies according not only to secretagogues such as glu-
cose but also as a function of the insulin demand from target
tissues. A feedback loop also exists between insulin sensitivity
and insulin secretion, such that changes in sensitivity of
peripheral tissues are balanced by corresponding increases in
secretion, insuring preservation of euglycemia [1, 2]. A rise
in the insulin demand occurs during normal body growth
(from birth to early childhood periods), as a consequence of
an increase in body weight and during pregnancy. To meet
the requirement of insulin, beta-cells adapt both their mass
and function to release sufficient insulin to maintain blood
glucose homeostasis [1, 2]. Evidence for this compensatory
process has been consistently provided by rodent models of
obesity and diabetes and notably by the emerging availability
of human pancreas necropsies [2, 3]. Indeed, beta-cell mass
and function in pancreases of nondiabetic or prediabetic
obese individuals is larger than in lean normoglycemic
subjects [3–5]. In obesity beta-cell mass increases by 30–
40% whereas insulin secretory output augments by 100%
[6]. Conversely, diminished beta-cells mass and function
contribute to the decrease in plasma insulin level in individ-
uals with diabetes. Postmortem histology further a 20–65%
decrement in beta-cell mass in islets from obese individuals
with type 2 diabetes (T2D) when compared to BMI-matched
nondiabetic subjects [3–5, 7–9]. This adaptive capacity of
human islets to obesity has been confirmed in experimental
murine models [10, 11]. In one study, human islets were
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grafted in an immunodeficient mouse strain sensitive to high
fat-diet (HFD-)induced obesity [10].This mice model is used
for longitudinal studies of islets exposed to an obesogenic
environment [10]. Enlarged volume of human beta-cells
was observed in xenotransplanted mice fed with HFD for
12 weeks [10]. However, despite the gain of beta-cell mass
and the increase in insulin expression, these mice displayed
hyperglycemia. This study confirms the requirement for an
appropriate number of functional beta-cells to circumvent
insulin resistance [10]. Therefore, insulin deficiency in T2D
may in part result from an insufficient number of functional
beta-cells under conditions such as ageing, weight gain, or
metabolic alterations [7, 12, 13].
Despite intensive research, current treatments of T2D do
not prevent the appearance of long-term complications and,
over time, can also become inefficient to insure appropriate
glycemic control. This inefficacy may result from the fact
that available strategies do not permit to protect beta-cells
against their inescapable decline. The existing therapies with
exogenous insulin or hypoglycemic agents for type 1 diabetes
(T1D) are also unsatisfactory, since they do not offer a cure
and are mostly insufficient for preventing the secondary
complications associated with diabetes [14]. Transplantation
of a sufficient number of pancreatic beta-cells can normalize
blood glucose levels and may prevent the complications of
diabetes [15]. However, immunosuppressive therapy is a cur-
rent obstacle in transplantation and beta-cells from cadaveric
donors are in such a short supply that transplants can be
provided only to a limited number of patients. Regeneration
of the functional beta-cell mass in patients could potentially
represent an alternative to transplantation. In view of the
inefficacy of the current treatments and the increasing global
prevalence of diabetes [16], it is urgent to intensify efforts
for developing new therapeutic strategies for both T1D and
T2D. In this regard, it is tempting to postulate that strategies
aiming at improving beta-cell function and mass plasticity as
well as beta-cell survival under proapoptotic conditions could
be of major interest for designing innovative therapeutics to
prevent beta-cell decline and restore their functional adaptive
ability in diabetes.
Adaptive capacity of beta-cell mass and function depends
on the activity of transcriptional and translational regulators,
which tightly and timely modulate the expression of genes in
response to environmental cues. The noncoding microRNAs
(miRNAs) are extremely important to accomplish this task
[17]. MiRNAs act as translational repressors that bind to the
3󸀠UTR of target mRNAs, leading to translational inhibition
and/ormessenger degradation [18, 19]. EachmiRNA can have
hundreds of targets, thereby triggering pleiotropic effects in
beta-cells. This review provides insights into the pivotal role
ofmiRNAs in beta-cell adaptation and failure during diabetes
[20–26].
2. miRNAs Required for Beta-Cell
Specification Fate
The regulation of the beta-cell mass in adult life results
from the dynamic balance between proliferation, neogenesis,
and apoptosis. The mechanisms underlying the control of
these phenomena are participating also to normal pancreas
development, and thereby can help in understanding the
compensatory mechanisms elicited in response to environ-
mental cues and metabolic changes [27, 28]. The pancreas
derives from a pool of endodermal cells. At the initial stage,
the proliferation of the progenitor cells is stimulated by
growth factors and other signalling molecules produced by
the surrounding mesenchyme. This process is governed by a
sequential cascade including the appearance of neurogenin3
(Neurog3) [29]. The number of Neurog3 expressing cells
increases and peaks at embryonic day e15.5, after which the
level of this transcription factor gradually declines [29]. Neu-
rog3 is undetectable in insulin- and glucagon-producing cells,
suggesting that it is not necessary for postnatal islet function
[29]. In fact, transient expression of Neurog3 is critical for
temporarily allowing the lineage-committed transcription
factors required for the differentiation of the endocrine
progenitor cells, which will give rise to the endocrine cell
subtypes within the islets [29–31]. Ablation of Neurog3
prevents the generation of all pancreatic endocrine cells
in mice. Evidence for a role of miRNAs in the control of
Neurog3 during pancreas development has been provided by
a mice model in which the pancreatic expression of the large
majority of the RNAs has been abolished.miRNAs are usually
generated by RNA polymerase II.This enzyme initially yields
pre-miRNA molecules containing a hairpin loop, which
undergoes sequential processing including cytosolic excision
of the hairpin by the ribonuclease (RNase) type III Dicer1
[32]. In mammals, the loss of the RNase III domain of
Dicer1 blocks the formation of most miRNAs [32]. The islet-
specific Dicer1 knockout mice generated using the Pdx1-
Cre transgene survive until birth but fail to grow and die
by P3 [20]. The pancreas of Dicer1-null mice displays an
almost absolute loss of insulin-producing cells and there
is a marked decrease in other cell types at e18.5 [20]. The
defect of endocrine cells observed in the Dicer1 knockout
mice is associated with an increase in Hes1 level and a
reduction in the formation of endocrine progenitor cells
expressing Neurog3 [20]. Besides the induction of Notch
signaling by Hes1, a possible synergistic mechanism account-
ing for Neurog3 inhibition during pancreas development
could be a direct control by miRNAs. Demonstration of this
hypothesis has been attempted in a model for pancreatic
regeneration [33]. Regeneration of beta-cells following a 50
or 70% pancreatectomy is not associated with induction of
Neurog3 protein in progenitor cells despite the presence of
the transcript. This result prompted the authors to propose
a posttranslational control of Neurog3 expression mediated
by miRNAs [33, 34]. Results from global miRNA profiling
in regenerating pancreas after partial pancreatectomy have
highlighted upregulation of 4 miRNAs including miR-15a,
miR-15b, miR-16, and miR-195 (Table 1) [33]. All the four
miRNAs are predicted to target the Neurog3 mRNA, sug-
gesting that they could contribute to the posttranslational
regulation of the transcription factor [33]. Whether these
miRNAs individually contribute to pancreas development
has not yet been investigated.
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Table 1: miRNAs required for beta cell specification fate and pan-
creas development.
miRNAs Known functionaleffect Targets References
mir-15a,
miR-15b,
miR-16, and
miR-195
Pancreas
development,
beta-cells fate and
regeneration
Neurog3 [33]
miR-375 Beta- and alpha-cellsexpansion [42]
miR-7a Beta-cellproliferation
mTOR
pathway
components
[44, 45, 48]
miR-124a Pancreasdevelopment Foxa2 [33]
3. miRNAs Are Required for Proliferation of
Progenitor Cells and Mature Beta-Cells
When progenitor cells start expressing insulin they stop
dividing. However, the beta-cell mass continues to expand
during fetal and postnatal growth [28, 35–37]. A process
that could account for beta-cell mass expansion in rodent is
replication. In normal rats, the beta-cell population approx-
imately doubles each day starting from the 16th day after
conception [36]. After birth the beta-cell population still
grows but during adult life at a much slower pace [37–
39]. A role for miRNAs in the control of differentiated
beta-cells has been highlighted by the generation of a mice
model with beta-cell specific ablation of Dicer1. Disruption
of the enzyme using the rat insulin promoter 2 (RIP-)Cre
transgene leads to alteration in islet morphology, reduction
in beta-cell number, and impairment in glucose-induced
insulin secretion [40, 41]. Marked perturbations in beta-cell
expansion and mass have been reported in knockout mice
for individual miRNAs. The first one for which a major role
in pancreatic development has been demonstrated is miR-
375 (Table 1) [22, 42]. This miRNA is highly enriched in
human and mice beta-cells [22]. The importance of miR-
375 in pancreatic endocrine cell development has emerged
from studies in zebrafish embryos [43]. Injection of anti-miR-
375 morpholinos into one- or two-stage embryos resulted
in disruption of the islet cell phenotype [43]. The miR-375
KO mice have been instrumental for unveiling a role for
this miRNA in beta-cell expansion besides its involvement
in the control of glucose-induced insulin secretion [42]. A
30–40% decrease in beta-cell mass has beenmeasured within
islets from these mice and, strikingly, a 1.7-fold increase
in alpha-cells [42]. The combined hyperglucagonemia and
hypoinsulinemia inmiR-375 KO animals led them to develop
hyperglycemia [42]. Other miRNAs such as miR-7a have
been shown to potentially contribute to beta-cell expansion
during pancreatic organogenesis. miR-7a belongs to the
evolutionarily conserved miR-7a/b family and is abundant in
beta-cells of rodent and human islets [44]. Inhibition of miR-
7a activates themammalian target of rapamycin (mTOR, a.k.a
FRAP, RAFT, or RAPT) pathway in themouseMIN6 insulin-
producing cells and in primary mouse islets [45]. Activation
of this evolutionarily conserved serine/threonine protein
kinase promotes beta-cell replication and expansion of the
beta-cell mass [46, 47]. The mTOR pathway can be divided
into two biochemically and functionally distinct multicom-
ponent complexes termed mTOR complex 1 (mTORC1) and
mTOR complex 2 (mTORC2) [48]. The two complexes are
pivotal for the control of beta-cell mass although their down-
stream targets are distinct [48]. Disruption of miR-7a leads to
upregulation of the downstream targets ofmTORC1, p70S6K,
eukaryotic translation initiation factor 4E (eIF4E) and two
MAPK-interacting kinases that phosphorylate eIF4E, as well
as one of the essential TORC2 components, Mapkap1 [48].
Consequently, activation of the mTOR pathway caused by
the suppression of miR-7a results in increased proliferation
of beta-cells. So far, independent studies have shown that
human beta-cells can proliferate within islets or under in
vitro condition but the rate is extremely low [3, 49–53]. It is
noteworthy that the authors have observed a nearly 30-fold
increase in human beta-cell proliferation upon the reduction
of miR-7a level [48].
4. miRNAs Regulating Nutrient-Induced
Insulin Secretion and Insulin Production
The function of mature beta-cells is to release appropriate
amounts of insulin in response to its main physiological
stimulus, glucose, and to other secretagogues, including the
incretin hormone glucagon like peptide-1 (GLP-1) and its
mimetics [54]. In fact, GLP-1 potentiates glucose-induced
insulin secretion by interacting with the GLP-1 receptor
[54]. In human islet beta-cells, efficient incretin-stimulated
insulin secretion relies on the recruitment of a highly coor-
dinated subnetwork of beta-cells [55]. Activation of GLP-
1R elevates cAMP levels, which in turn promote insulin
secretion via both protein kinase A (PKA-)dependent and
PKA-independent mechanisms [54]. A downstream long-
term effect resulting from PKA activation consists of the
modification of the expression of several genes [54, 56].
Such modulation is deemed to contribute to the plastic-
ity of the secretory response to GLP-1 and glucose. The
expression of miR-375 has been shown to be controlled
by the activation of the cAMP/PKA pathway [57]. Indeed,
incubation of rat insulin-producing cells with the GLP-1
mimetic exendin-4 leads to a decrease in miR-375 levels in
a mechanism that involves PKA [57]. Reduction of miR-
375 occurs also in response to glucose but in this case in a
cAMP/PKA-independent manner [57, 58]. Decrease of miR-
375 in the mouse insulin-producing MIN6 cells enhances
insulin secretion, whereas overexpression of this miRNA
hampers the ability of the cells to secrete in response to
glucose [22]. One of the targets of miR-375 that accounts
for glucose-induced insulin secretion ismyotrophin (Table 2)
[22]. Silencing of the latter mimics the effect of miR-375
on insulin secretion [22]. Thus, the drop of miR-375 caused
by glucose and exendin-4 could be beneficial for insulin
secretion by increasing the expression of myotrophin [22].
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Table 2: miRNAs regulating nutrient-induced insulin secretion and
insulin gene expression.
miRNAs Known functionaleffect Targets References
miR-9 Insulin secretion Onecut-2, Sirt1 [26]
miR-21 Insulin secretion VAMP2, Rab3a [93]
miR-29a, b Insulin secretion Mctl1 [71]
miR-30d Insulin transcription [63]
miR-34a Insulin secretion VAMP2, Rab3a [93]
miR-96 Insulin secretion Noc2 [24]
miR-124a Insulin secretion Rab27a, Noc2,MCT1 [24, 71]
miR-204 Insulin transcription MafA [65]
miR-375 Insulin transcription,insulin secretion
PDK1,
myotrophin [22, 58]
Another miRNA required for insulin secretion is miR-9
(Table 2). This miRNA is upregulated during differentiation
of human embryonic stem cells and during the formation
of cells of both neuronal and pancreatic lineages [21, 59].
Moreover, appropriate expression of this miRNA is required
for mature beta-cell tasks and probably during development.
Either overexpression or silencing of miR-9 is deleterious for
the secretory capacity of beta-cells [26]. In fact, manipulation
of miR-9 level impinges the expression of the Onecut2 (Oc2)
transcription factor, which in turn hampers the content of the
secretory machinery component Slp4 [26]. As consequence
of the increased level of Slp4, beta-cells insulin secretion in
response to secretagogues is impaired [26].
Slp4 belongs to the Rab GTPase effector family that
includes also RIM2, MyRIP/Slac2c, and Noc2 [60]. In beta-
cells, these effectors are associated with Rab3a and/or Rab27a
and regulate the assembly of the SNARE proteins SNAP25,
Syntaxin-1, and VAMP-2, thereby controlling insulin exo-
cytosis [60]. The expression of SNAP25, Rab3a, Rab27, and
Noc2 are regulated by miR-124a in mouse insulin-producing
cells [24]. Overexpression of miR-124 increases SNAP25 and
Rab3a levels but reduces those of Rab27 and Noc2 [24]. miR-
96 is also expressed in beta-cells and controls the expression
of Slp4 and Noc2 [24]. The level of Slp4 increases and this
of Noc2 decreases in cells that overexpress miR-96 [24]. The
key role of miR-124a and miR-96 in the control of the level of
several critical components of machinery governing insulin
secretion suggests a potential participation of these miRNAs
in the terminal differentiation of beta-cells.
Mature beta-cells have the exclusive task to produce
insulin. At normal glucose concentrations, insulin represents
approximately 1/3 of the synthesized proteins [61]. However,
this ratio can reach almost 1/2 at 7mmol/L glucose [61].
The increase of insulin production occurring within the
first minutes to hours upon glucose exposure is mostly
achieved through enhanced protein synthesis and mRNA
stabilization. In contrast, at later time points it is mainly
due to transcriptional and posttranscriptional mechanisms
[62]. The long-term control of insulin mRNA levels trig-
gered by glucose contributes to the replenishment of the
hormone content and is achieved through the activation of
transcriptional regulators and miRNAs. Culture of insulin-
producing cells at high glucose concentration affects the
expression of more than hundred miRNAs, including miR-
30dwhich is able to increase insulin gene expression [63]. Key
transcription factors involved in glucose-mediated control of
insulin expression have been described in detail elsewhere
[64]. These factors include v-maf avian musculoaponeurotic
fibrosarcoma oncogene homolog A (MAFA), pancreatic and
duodenal homeobox 1 (PDX1), and neurogenic differentia-
tion 1 (NeuroD) [64]. MAFA abundance is under the control
of miR-204. In diabetes, the beta-cell expression of this
miRNA increases in response to the elevation of the cellular
redox regulator thioredoxin-interacting protein. In turnmiR-
204 reduces the expression of insulin [65]. Regulation of
insulin transcription during development involves additional
transcription factors including the members of the Onecut
(OC) family [66]. In view of these findings, we tested the role
of Oc2 and indirectly miR-9 in the control of insulin pro-
duction. We found that overexpression or silencing of miR-
9 decreases insulin expression (Figure 1(a)), indicating that
adequate levels of this miRNA are required for maintaining
optimal insulin mRNA levels. In addition, elevated amounts
of miR-9 reduce the activity of a luciferase reporter construct
driven by the rat insulin promoter (Figure 1(b)), suggesting
a role for miR-9 in the control of insulin gene expression.
Inactivation of OC-2 using a dominant negative construct
mimics the effect of miR-9 on insulin promoter (Figure 1(b)).
Thus, besides regulating glucose-induced insulin secretion,
miR-9 appears also to be crucial for maintaining insulin
mRNA levels in a mechanism probably involving Oc2.
Accumulation of insulin mRNA in response to glucose relies
on nuclear translocation of PDX1. Glucose-induced nuclear
import of the transcription factor is triggered by activation
of the phosphatidylinositol 3-kinase (PI3K) pathway [67].
This signaling cascade results in the phosphorylation of
protein kinase B by the 3-phosphoinositide-dependent kinase
1 (PDK1) [68]. Beta-cell specific knockout of PDK-1 leads to
a reduction in islet cell mass and the development of overt
diabetes [69]. PDK1 has been identified as a target of miR-
375 [58]. Overexpression of miR-375 in rat insulin-producing
INS-1E cells decreases the expression of PDK-1, leading to
reduction of insulin mRNA level [58].
Numerous genes that are required for glucose-induced
insulin secretion and cells survival are highly or selectively
expressed in beta-cells [60]. In addition, proper control of
glucose-induced insulin secretion involves the absence or the
low expression of “disallowed genes” including those coding
for lactate dehydrogenase A (Ldha) and monocarboxylate
transporter-1 (Mct1) [70]. Overexpression of ldha in insulin
secreting cells affects glucose-induced insulin secretion. Islets
of individuals with diabetes display an increase in the
expression of LDHA when compared to controls [70]. Beta-
cells elevation of MCT1 in mice fosters pyruvate-stimulated
insulin secretion, thus leading to hyperinsulinism during
exercise [71]. The absence of MCT1 in beta-cells could hence
prevent inappropriate insulin secretion elicited by pyruvate.
Amechanism that accounts for repression of the “disallowed”
MCT1 in beta-cells could involve some miRNAs. The MCT1
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Figure 1: Role ofmiR-9 in insulinmRNA and promoter activity. (a) Effect ofmiR-9 on insulinmRNA.TheRNAduplex containing themature
form of miR-9 [26] and a siRNA directed against miR-9 (si-miR-9) or a control oligonucleotide was transfected in MIN6 cells for 48 hrs. The
expression of the preproinsulin mRNA was measured by quantitative PCR.ThemRNA level was normalized against the housekeeping acidic
ribosomal phosphoprotein P0 gene (Rplp0) and the expression level in cells transfected with the control siRNA was set to 100%. Data are the
mean of ± SEM of 3 independent experiments. (b) Effects of miR-9 and dominant negative Oc2 mutant on the activity of an insulin reporter
construct in MIN6 cells. MIN6 cells were transiently transfected with miR-9 RNA duplexes containing the mature form of miR-9 [26] or
the dominant negative Oc2 mutant [26]. The cells were cotransfected with a luciferase reporter construct driven by a 600 bp fragment of
the rat insulin promoter (Ripluc) and with pRLSV40, a construct producing a renilla luciferase activity under the control of the constitutive
SV40 promoter. The firefly luciferase activity produced by Ripluc was normalized to the renilla luciferase activity to rule out differences in
the transfection efficiency. The empty pGL3 basic (luc) was used as control. Each experiment was performed at least three times in triplicate.
mRNA is a direct target of miR-29a, miR-29b, and miR-
124 [71]. From this example, it is possible that the miRNAs
contribute to the silencing of “disallowed” genes in beta-cells.
5. miRNAs Associated with
Compensatory Beta-Cell Mass Expansion
in Pregnancy and Obesity
Pregnancy is the strongest physiological stimulus inducing
beta-cell mass plasticity. The mass of beta-cells and their
secretory activity returns to prepregnancy levels within the
first 10 days following parturition in rodents [72, 73]. The
levels of four miRNAs including miR-144, miR-218, miR-
338-3p, and miR-451 are modified in islets from pregnant
rats when compared to age-matched animals (Table 3) [74].
The expression of these miRNAs returned to resting levels
after parturition [74]. In vitro experiments have confirmed
a role for miR-338-3p and miR-451 in the control of beta-
cell tasks [74].While miR-338-3p levels are diminished, those
of miR-451 are increased during pregnancy [74, 75]. Rodent
and human beta-cell expansion during pregnancy is likely to
occur thanks to enhanced proliferation combinedwith amin-
imal rate of apoptosis [72, 73, 76]. Overexpression of miR-451
does not increase the proliferation rate of insulin-producing
cells but this miRNA protects the cells against apoptosis
elicited by palmitate and cytokines [74]. Downregulation
of miR-338-3p appears to be even more important in the
adaptation of beta-cells during gestation. Indeed, reduction
of miR-338-3p expression leads to a specific increase in
proliferation of cultured insulin-producing islet cells and
transplanted pseudoislets cells [74, 75]. Furthermore, as is
the case for miR-451 overexpression, reduction of miR-
338-3p protects the beta-cells against apoptosis evoked by
diabetogenic conditions such as chronic exposure to elevated
palmitate or cytokines, indicating that the decrease of miR-
338-3p is pivotal for compensatory beta-cell mass expan-
sion during pregnancy. Despite these proproliferative and
antiapoptotic effects,miR-338-3p downregulation ormiR-451
overexpression did not significantly impact insulin content
and glucose-induced insulin secretion, indicating that upon
changes in the level of these miRNAs the beta-cells retain a
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Table 3: miRNAs associated with compensatory beta-cells.
miRNAs Cell types/models Expressionchange Known functional effect References
miR-132 Islets of prediabetic db/db mice Up Beta-cells proliferation [84]
miR-184 Down
miR-338-3p
Islets of pregnant rats and islets of
prediabetic db/db mice and obese mice fed
with a high fat diet Down
Beta-cells
proliferation/antiapoptotic
[74]
Cells cultured with estradiol or incretins
miR-451
Islets of pregnant rats, islets of prediabetic
db/db mice and obese mice fed with a high
fat diet
Up Antiapoptotic [74]
fully differentiated phenotype. The beta-cell mass not only
increases during pregnancy but also during insulin-resistance
and obesity [1].The gain of beta-cellmass compensates for the
increased insulin demand from peripheral tissues, thereby
maintaining euglycemia [1]. An increase of miR-451 and a
decrease of miR-338-3p analogous to those observed in islets
of pregnant rats are also detected in islets of obese mice fed
with high fat diet [74]. Moreover, diminution of miR-338-
3p occurs in young still normoglycemic but already obese
db/db mice, indicating a broader role for this miRNA in
physiological islet adaptation [74]. The exact mechanisms
governing the expression ofmiR-338-3p remain to be defined.
During pregnancy, the level of estradiol and incretins such as
GLP-1 is elevated [77, 78] and may be responsible for beta-
cell proliferation [77, 79, 80]. GLP-1 is also increased in obese
individuals possibly contributing to beta-cell mass expansion
[77]. Interestingly, agonists of the GPR30 estradiol receptor
and of the GLP-1 receptor are able to decrease miR-338-3p
levels in beta-cells via a signalling cascade involving a rise in
cAMP and the activation of PKA [74].
6. miRNAs Associated with Beta-Cell
Dysfunction under Diabetogenic Condition
The compensatory processes described above precede beta-
cell decline during the development of diabetes [2, 81]. Failure
in mechanisms that maintain the adaptive capacity of islet
beta-cells may account for impaired beta-cell function and
mass. This hypothesis has been tested by measuring the
expression of miRNAs in islets of leptin receptor deficient
db/db mice of different ages. The db/db mice at 6 weeks
of age are obese and insulin resistant [82, 83]. However,
normoglycemia is preserved and manifestation of diabetes
is delayed because of increased functional beta-cell mass.
Besides the decreased expression of miR-338-3p [74], the
adaptive islets of these mice display variations in other
miRNAs (Table 4) [84]. These include an increase in miR-
132 and a decrease in miR-184, miR-203, and miR-210 [84].
Overexpression of miR-132 and inactivation of miR-184
trigger proliferation in dispersed beta-cells from rat islets
[84]. In contrast, in vitro reduction of miR-203 and miR-
210 increases rat beta-cell apoptosis [84]. The reduction
of miR-210 and miR-184 is more pronounced in isolated
islets from overtly diabetic db/db mice, suggesting that an
unbalance in the level of these miRNAs can result in a switch
from beta-cell adaptation to programmed cell death [84]. In
addition, changes in the expression of miR-199a-3p andmiR-
383 appear to contribute to beta-cell failure in diabetic db/db
mice. Indeed, upregulation of miR-199a-3p and diminution
in miR-383 increase rat beta-cell apoptosis in vitro [84].
At the present time, the miRNAs that are associated with
compensatory human islets remain to be identified. So far,
one study has quantified the miRNAs level in a small group
of islets of individuals with and without type 2 diabetes [85].
Only an increase in the miR-187 level is associated with beta-
cell failure in diabetes [85]. This result suggests that different
miRNAs account for adaptation and decline of beta-cells in
human and rodents during diabetes.
Chronic elevation in circulating levels of nonesterified
free fatty acids (NEFAs) is associated with obesity and is an
independent predictor of T2D development [86, 87]. Numer-
ous studies have highlighted palmitate, the most abundant
NEFA in blood, as a detrimental factor promoting insulin
resistance and beta-cell dysfunction. db/db mice display
an abnormally increased blood NEFA concentration [88].
Beta-cell failure elicited by this lipid includes a decrease of
insulin expression, impaired secretory capacity in response
to nutrients and/or loss of beta-cell mass via apoptosis [3,
4, 89]. Elevated palmitate levels are thought to synergize
with chronic hyperglycemia in promoting beta-cell failure
in obesity-associated diabetes [90]. The decrease in miR-
184, miR-203 and miR-383 is mimicked by chronic expo-
sure of beta-cells to palmitate and/or glucose, suggesting a
role for glucolipotoxicity in the variation of these miRNAs
observed in islets of diabetic mice [90]. Additional miRNAs
are changed in db/db mice, probably contributing to beta-
cell dysfunction and death [91]. The expression of miR-
34a and miR-146 is indeed augmented in islets of these
mice [91]. Elevation in their levels causes dysfunction and
apoptosis and mimics the harmful effects of palmitate in
cultured islets [91]. Palmitate also triggers beta-cell dysfunc-
tion by an indirect mechanism that involves activation of the
inflammatory process [92]. Continuous infusion of palmitate
in mice evokes an increase in M1-type proinflammatory
monocyte/macrophages infiltrationwithin islets [92]. Several
studies contend a role for low grade inflammation as a major
issue, which links obesity to the development of diabetes
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Table 4: miRNAs associated with beta-cell failure.
miRNAs Cells type/models Expression change Known functional effect References
miR-21 Cells cultured with cytokines Up Glucose-induced insulinsecretion and proapoptotic [93]
miR-34a and
miR-146a, b
Islets of diabetic db/db mice, cells cultured
with cytokines or palmitate Up
Glucose-induced insulin
secretion and proapoptotic [91, 93]
miR-184 Islets of diabetic db/db mice, cells culturedwith glucolipotoxic condition Down
Glucose-induced insulin
secretion [84, 90]
miR-187 Islets of individuals with type 2 diabetes Up Glucose-induced insulinsecretion [85]
miR-199a-3p Islets of diabetic db/db mice Up Proapoptotic [74]
miR-203 and
miR-383
Islets of diabetic db/db mice, cells cultured
with glucolipotoxic condition Down Proapoptotic [90, 93]
miR-210 Islets of diabetic db/db mice Down Proapoptotic [84]
Table 5: Global miRNA profiling of MIN6 cells cultured with human native and oxidized LDL with or without HDL. We compared by
microarray analysis the expression of 350 miRNAs in MIN6 cells that were incubated with 2mmol/L of human native (Na LDL) or oxidized
LDL (oxLDL) cholesterol plus or minus 1mmol/L of HDL for 72 hrs.
Microarray Name NaLDL oxLDL Change (log2) Expression change oxLDL oxLDL + HDL Change (log2)
NaLDL versus
oxLDL
mmu-miR-9 1 622.36 739.3 −1.16 Down 2 417.08 3 407.71 0.46
mmu-miR-21 6 073.84 15 447.81 1.37 Up 23 042.48 11 193.24 −1.01
mmu-miR-98 7 909.01 2 817.75 −1.5 Down 12 432.59 16 691.57 0.42
mmu-miR-192 222.59 514.66 1.02 Up 1 076.26 732.38 −0.51
mmu-miR-325 1 018.38 462.41 −1.16 Down 1 757.68 2 642.59 0.65
mmu-miR-342-3p 2 181.11 1 326.71 −0.73 Down 2 483.59 4 337.97 0.79
mmu-miR-346 904.18 505.43 −0.85 Down 485.7 770.91 0.64
mmu-miR-374 5 082.44 1 887.82 −1.43 Down 5 022.55 7 143.28 0.54
Mmu-miR-708 366.85 712.44 0.94 up 825.11 402.52 −1.06
mmu-miR-801 488.33 915.52 0.85 up 521.23 216.79 −1.29
[7, 89]. Interestingly, the levels of miR-34a and miR-146 are
elevated by proinflammatory cytokines in isolated human
islets and insulin-producing cells, indicating that the signal-
ing cascades causing beta-cell failure elicited by palmitate
and cytokines may converge and result in the activation of
the same miRNAs [93]. Beside these two miRNAs, cytokines
induce also the expression of miR-21 [93]. This miRNA plays
a role in cell survival and can also affect glucose-induced
insulin secretion by modulating the levels of components of
the secretory machinery [93].
Besides chronic hyperlipidemia and hyperglycemia,
patients with diabetes display an increased ratio of oxidized
LDL over native LDL [94–96].The concentration of oxidized
LDL is already elevated in prediabetic individuals [97]
and increases throughout the duration of the disease [98].
The rise of oxidized LDL is thought to result, in part,
from the reduced antioxidant property of HDL [94, 98–
100]. Elevation of oxidized LDL apparently correlates
with reduction of plasma HDL concentration, a hallmark
of metabolic syndrome [101]. Importantly, infusion of
recombinant HDL in patients with T2D reduces glycemia
[101]. The beneficial effect of HDL relies on both improved
insulin secretion and glucose uptake in muscles [101].
Several independent groups, including ours, have confirmed
the protective effect of HDL against the harmful effects
evoked by oxidized LDL in beta-cells [94, 95, 101, 102].
Coincubation of islets and insulin-producing cells with
HDL prevents the defective insulin production and glucose-
induced insulin secretion observed in the presence of
2mM oxidized human LDL cholesterol [94, 95, 101, 102].
Moreover, cell survival is strongly improved in the presence
of HDL [94, 95, 101, 102]. Although native LDL above 3.1mM
cholesterol perturbs insulin secretion and cell survival
[103, 104], at 2mM cholesterol the lipoprotein does not affect
the accomplishment of the tasks and the viability of beta-cells
[94, 95, 101, 102]. A global microarray profiling was done
to investigate the contribution of miRNAs in the adverse
effects elicited by oxidized LDL. The modified lipoprotein
modified the expression of a set of 10 miRNAs (Table 5). The
expression changes were further prevented by coincubation
with HDL (Table 5). However, quantitative PCR analysis
confirmed the variation for only 5 of them (Figure 2).
The expression of miR-9 was decreased, whereas that of
miR-21 was increased in insulin-secreting cells cultured with
oxidized LDL particles (Figure 2). As already mentioned,
upregulation of miR-21 hampers glucose-induced insulin
secretion by modifying the expression of components of
the secretory machinery [26, 93]. Moreover, appropriate
8 Journal of Diabetes Research
40
80
120
miR-9
m
iR
 ex
pr
es
sio
n 
(%
 o
f c
on
tro
l) 
0
miR-98
40
80
120
m
iR
 ex
pr
es
sio
n 
(%
 o
f c
on
tro
l) 
0
100
300
miR-21m
iR
 ex
pr
es
sio
n 
(%
 o
f c
on
tro
l) 
200
0
40
120
200
miR-325m
iR
 ex
pr
es
sio
n 
(%
 o
f c
on
tro
l) 
0
Vehicle
NaLDL
oxLDL
oxLDL + HDL
40
80
120
miR-374
m
iR
 ex
pr
es
sio
n 
(%
 o
f c
on
tro
l) 
0
Figure 2: Identification of miRNAs differentially expressed in MIN6 cells cultured with human native and oxidized LDL. The expression
of the indicated miRNAs was measured by quantitative RT-PCR in MIN6 cells that were cultured with vehicle, 2mmol/L of oxidized LDL
(oxLDL), and native LDL (NaLDL), plus orminus 1mmol/LHDL-cholesterol for 72 hrs. Human plasma LDL andHDL fractions were isolated
by sequential ultracentrifugation (LDL density, 1.063) as described [95]. Oxidation of LDL particles was done by incubation of 1mg LDL
protein/mL PBS with 5𝜇mol/L CuSO4 at 37∘C for 6–8 h [95].The oxidation reaction was verified as previously described by determining the
lipid peroxide content [95]. The results are expressed as fold changes and correspond to the mean ± SD.
levels of miR-9 level are required to achieve optimal insulin
expression (Figure 1(b)). Thus, the changes in these two
miRNAs may contribute to beta-cell dysfunction provoked
by the oxidized lipoprotein. Further studies will be needed
to determine whether the decrease of miR-98, miR-325, and
miR-374 (Figure 2) also contributes to the loss of specific
beta-cell tasks and increased death caused by oxidized LDL.
It is widely accepted that the beta-cell decline in dia-
betes relies on genetic factors [105]. The contribution of
genetic factors varies according to the forms of diabetes. In
monogenic and dominant forms of diabetes, mutations in a
single gene can lead to beta-cell failure and thereby to the
development of the disease [105, 106]. The maturity-onset
diabetes of the young (MODY) is a familial monogenic form
of early-onset type 2 diabetes, which usually develops in
childhood, adolescence, or young adulthood [105]. MODY
is now classified in the group of “genetic defect in beta-
cell function” with a subclassification according to the gene
involved [105]. The most common mutation in the gene
encoding transcription factor 1 (TCF-1)/hepatocyte nuclear
factor 1a (HNF1A) that causes MODY3 is a frame shift
mutation in exon 4, Pro291fsinsC-HNF1A [105–107]. The
mutation within the gene results in a truncated protein that
plays as a dominant negative action. Overexpression of this
mutant in insulin-producing cells hampers glucose-induced
insulin secretion [108]. Impaired insulin secretion caused by
the mutated protein is associated with an elevation in the
levels of miR-103 and miR-224. Thus, genetic variation may
impact the expression of miRNAs, potentially synergizing
with environmental stressors in triggering islet beta-cell
dysfunction in diabetes [107].
7. Conclusion and Perspectives
miRNAs are essential regulators of beta-cell function as
evidenced by the growing number of these small RNA
molecules, which play a central role in normal develop-
ment, plasticity, and dysfunction of insulin-secreting cells.
Besides their intracellular function, a large set of miRNAs
are released in stable form in body fluids including blood
and urine. Variations in the blood miRNA pool are emerg-
ing as promising biomarkers of several diseases including
diabetes [109]. Indeed, circulating miRNAs including miR-
103 and miR-224 have been found in the blood of patients
with diabetes [108]. Transport of miRNAs within blood is
achieved through different pathways involving the associa-
tion with HDL particles, exosomes, and other proteins such
as argonaute 2 or nucleophosmin 1 [109, 110]. Defective
beta-cells can release miRNAs into bloodstream following
pathophysiological conditions. Future investigations should
puzzle out the physiological meaning of these circulating
RNAs and determine whether the pool of miRNAs released
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in the blood differs according to the activation state of beta-
cells. If so, monitoring these miRNAs would be insightful
for monitoring whether beta-cells are in a compensatory
or a failure condition. The extraordinary amount of new
information provided by the discovery of the miRNAs has
drawn researchers and clinical diabetologist to explore the
potential involvement of another emerging class of non-
coding RNAs, the long noncoding RNAs (lncRNAs) [111].
LncRNAs represent a heterogeneous population of RNA
molecules longer than 200 nucleotides. The function of
most of them remains unknown although several lncRNAs
exert nonredundant roles in processes such as transcriptional
regulation and survival [112–114]. A large number of lncRNAs
is also present in human islets and some of them have their
expression modified in diabetes [111]. There is no doubt that
the coming years will witness the emergence of lncRNAs as
additional players in the control of beta-cell function and/or
in the regulation of lineage plasticity. The discovery of the
regulatory potential of this emerging RNA world promises
to unveil new opportunities for developing drugs capable of
protecting beta-cells in the context of diabetes.
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